Immune checkpoint inhibitors for treatment of biliary malignant tumors
10.3969/j.issn.1001-5256.2022.05.005
- VernacularTitle:胆道系统恶性肿瘤免疫检查点抑制剂治疗
- Author:
Guoming SHI
1
;
Yanzhi PEI
1
;
Pinxiang LU
2
;
Jun CAO
3
;
Jian ZHOU
1
;
Jia FAN
1
Author Information
1. Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2. Department of General Surgery, Xuhui District Central Hospital, Shanghai 200032, China
3. Department of Interventional Oncology, Dahua Hospital, Xuhui District, Shanghai 200032, China
- Publication Type:Discussions by Experts
- Keywords:
Biliary Tract Neoplasms;
Drug Therapy, Combination;
Molecular Targeted Therapy;
Immunosuppressive Agents
- From:
Journal of Clinical Hepatology
2022;38(5):998-1001
- CountryChina
- Language:Chinese
-
Abstract:
Biliary malignant tumors have an insidious onset and rapid development, and most patients have lost the opportunity for radical surgery at initial diagnosis and often have poor prognosis. Gemcitabine-based chemotherapy is the first-line treatment for biliary malignant tumors, but with a limited clinical effect. The improvement in next-generation sequencing technology provides the possibility for the precise treatment of biliary malignant tumors, but the application and development of the precise treatment of biliary malignant tumors are limited by the low positive rate of targets and the poor accessibility of therapeutic drugs. The advent of the era of immunotherapy represented by the immune checkpoint inhibitor PD1/PD-L1 monoclonal antibody brings a promising future for the treatment of malignant tumors, including biliary malignant tumors. Combined chemotherapy and/or targeted therapy based on immune checkpoint inhibitors has shown a good effect in the treatment of biliary malignant tumors, which is the direction of the treatment of advanced biliary malignant tumors in the future.
